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Abstract Proflavin can be used to study the interactions of
inhibitors and substrates with thrombin by monitoring the
changes in the visible absorption spectrum that occur on dye
displacement. We have used microspectrophotometric methods to
investigate the binding of proflavin to crystals of an K-thrombin-
hirugen complex and have determined the structure by X-ray
crystallography. The proflavin molecule binds in the S1 pocket of
the enzyme with one of the amino groups hydrogen bonded to the
carboxylate of Asp-189 while the protonated ring nitrogen is
hydrogen bonded to the carbonyl of Gly-219. This result
indicates that the proflavin displacement assay can be used to
specifically monitor the binding of inhibitors to the S1 pocket.
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1. Introduction
The thrombin sequence numbering based on topological
similarities with chymotrypsinogen [1]. PPACK residue num-
bers are primed. Sn and Pn represent inhibitor (or substrate)
and proteinase sites prior to the cleavage site [31].
The design of speci¢c, non-peptidic, mechanism-based in-
hibitors of human K-thrombin is currently of great interest for
the development of potential antithrombotic drugs. Thrombin
is a serine proteinase with trypsin-like speci¢city towards basic
residues, and has the typical structural features of this class of
enzymes. The three-dimensional structure of human K-throm-
bin in various complexes with substrates and inhibitors have
been reported, allowing the details of the enzyme active site to
be elucidated [1^5]. The principal determinant of substrate
speci¢city is the S1 pocket, an elongated channel with Asp-
189 at the bottom, able to make salt bridges with arginyl and
more rarely lysyl P1 residues of the physiological substrates.
Near the entrance of the speci¢city pocket lies a hydrophobic
region, identi¢ed as the S2 site, ideally suited to the binding of
P2 proline and other medium-sized non-polar residues. The S2
cavity forms a single common hydrophobic surface with the
adjacent ‘aryl binding site’, found to bind the phenylalanine
P9 residue of the ¢brinopeptide A [6] and the D-phenylalanine
P3 residue of the non-physiological inhibitor PPACK [1].
The equilibrium and kinetic interactions of inhibitors and
substrates to thrombin can be studied spectrophotometrically
by monitoring the change in the visible absorption spectrum
that occurs on displacing pro£avin. Pro£avin is an acridine
dye that shows large absorption spectrum changes on binding
to the active sites of K-thrombin [7] and other proteolytic
enzymes such as trypsin [8] and chymotrypsin [9]. In the
case of chymotrypsin, pro£avin competes with substrates
such as indole and tryptophan derivatives, consistent with
the binding to the large hydrophobic S1 pocket of this pro-
teolytic enzyme. Analogously, the dye binds to a single spe-
ci¢c site on thrombin with micromolar a⁄nity (KdV20 WM),
competing both with the charged inhibitor p-aminobenzamid-
ine [7] and with the neutral indole and related compounds
[10]. The binding of benzamidine to the speci¢city pocket of
thrombin [11] and the displacement of pro£avin by indole [12]
lead to the idea that the acridine moiety binds adjacent to the
catalytic centre in an apolar region of the active site, in agree-
ment with the strong preference of thrombin for charged P1
side chains. On the other hand, pro£avin binding has been
used as a probe of the integrity of the trypsin S1 binding
pocket which has a very similar architecture to that of throm-
bin [13].
Here we report crystallographic and microspectrophotomet-
ric binding studies of the pro£avin dye to the active site of
human K-thrombin. These studies were carried out with crys-
tals of K-thrombin complexed with hirugen. The hirugen-
thrombin complex is the only crystal structure determined
so far with an unobstructed active site; the presence of hir-
udin-type peptides at the exosite of the enzyme has been
shown not to prevent the binding of active site directed in-
hibitors [4]. The results show that pro£avin binds in the S1
speci¢city pocket and suggest that the spectrophotometric dis-
placement assay can be used to screen for binding of com-
pounds in the S1 pocket.
2. Materials and methods
2.1. Crystallisation
Human K-thrombin was produced by activating prothrombin with
taipan-snake venom [14,15]. Activated K-thrombin was assayed by
measuring its amidolytic activity towards a chromogenic substrate
and puri¢ed by taking advantage of its highly speci¢c a⁄nity to hep-
arin, which was immobilised on a matrix support of sepharose [16].
Both prothrombin and snake venom V-3129 were purchased from
Sigma, as was the chromogenic compound S2238 (H-D-Phe-Pip-Arg-
p-nitroanilideW2HCl). The heparin-sepharose CL-6B a⁄nity column
was obtained from Pharmacia LKB Biotechnology. From about 4.5
Wmoles of prothrombin, around 1.5 Wmoles of pure active K-thrombin
were recovered and stored at a concentration of 10 mg/ml (0.27 WM)
in 20 mM Tris bu¡er at pH 6.0 and 750 mM NaCl. The hirugen
peptide was purchased from Bachem.
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An approximately 10-fold excess of hirugen was added to the K-
thrombin sample. The thrombin-hirugen complex solution was con-
centrated with a Centricon10 to 20 mg/ml in 20 mM Tris pH 6.0 and
375 mM NaCl. Monoclinic thrombin-hirugen crystals belonging to
space group C2 were grown according to Skrzypczak-Jankun et al.
[3] with polyethylene glycol (PEG) as precipitant. The crystals used in
this study were obtained using the vapour di¡usion method and mi-
cro-seeding techniques in 6 Wl hanging drops containing 10 mg/ml
thrombin-hirugen, 0.05 M HEPES bu¡er at pH 7.0, 0.25 M NaCl,
10^12% w/v PEG-4000 and by equilibrating the drops for one day
against 0.1 M HEPES pH 7.0, 0.2 M NaCl, 20^24% PEG-4000 at
18‡C. Crystals larger than 100 Wm in the smallest dimension usually
appeared in 10 days. Crystals were stabilised in 25% w/v PEG-4000,
0.2 M NaCl and 0.1 M HEPES pH 7.0. For di¡raction measurements
the crystals were soaked for 24 h into a stabilising solution containing
1.4 mM pro£avin. Pro£avin was purchased from Sigma.
2.2. X-ray data collection
X-ray data were collected at room temperature on a CAD4 Enraf-
Nonius di¡ractometer equipped with a FAST television area detector,
using an Enraf-Nonius FR571 rotating anode X-ray generator oper-
ated at 42 kV and 99 mAî . Oscillation frames with a width of 0.15
degree rotation were collected with exposure times of 60 s per frame.
The data from the FAST area detector were evaluated on-line using
the program MADNES [17]. Subsequent data processing and reduc-
tion were carried out using the CCP4 suite of programmes [18]. Sta-
tistics regarding the di¡raction data are summarised in Table 1.
2.3. Crystallographic re¢nement
The coordinates of the thrombin-hirugen complex [3] have been
used as starting model. Re¢nement was carried out using energy re-
strained least-squares re¢nement with the program X-PLOR [19]. Sev-
eral cycles of positional and isotropic temperature factors re¢nement
were followed by model inspection and manual intervention using the
program FRODO [20]. After this ¢rst round of re¢nement, the pro-
£avin model [21] was ¢tted into the electron density map, which
clearly showed the presence of the bound inhibitor in the active site.
The re¢nement proceeded until all uninterpretable di¡erence electron
density was less than four times the r.m.s. deviation from mean den-
sity. A total of three rounds of re¢nement were carried out giving a
crystallographic R-factor of 18.8%. The re¢nement parameters and
the quality of the ¢nal model are presented in Table 1.
2.4. Spectroscopic measurements
Spectroscopic data have been obtained by single crystal polarised
absorption microspectrophotometry [22,23]. For spectral measure-
ments, single crystals mounted in a £ow cell were placed on the stage
of a Zeiss MPM03 microspectrophotometer, equipped with a Glan-
Thompson prism to produce linearly polarised light. The absorbance
from the monoclinic crystals of thrombin-hirugen was measured with
light polarised parallel to the x and y optical axes, which were exper-
imentally determined by observing the extinction directions. Spectra
were recorded between 300 and 550 nm.
Small crystals of the thrombin-hirugen complex (about 50 Wm
thick) were stabilised and incubated with 0.1 mM pro£avin. The
reference spectrum of pro£avin in the suspending medium was re-
corded and the kinetics of the complex formation were monitored
by collecting polarised absorption spectra at di¡erent times (Fig.
1A). The kinetics are di¡usion limited and dependent on crystal
size. The dependence on concentration was also investigated by the
incubation of a crystal with pro£avin over the range 0.05 mM to 0.5
mM (Fig. 1B). Spectra were recorded after equilibrium was reached.
From a least-squares ¢t of these data to a binding isotherm, the
dissociation constant (Kd) was determined as 0.53 þ 0.07 mM. To
study the time dependence of the displacement of pro£avin by
PPACK, polarised absorption spectra were recorded from a crystal
preincubated in a 0.1 mM pro£avin solution and then transferred to a
solution containing pro£avin (0.1 mM) and PPACK (0.1 mM) (Fig.
1C).
3. Results and discussion
3.1. Absorption spectra
Pro£avin absorption spectra display di¡erent characteristics
depending on the polarity of the surrounding medium. The
444 nm absorption maximum of the free dye in saline solu-
tions [12,24] shifts to longer wavelength when polyethylene
glycol (PEG) is present. A red shift to 458 nm is observed
as 25% w/v PEG-4000 is added to the pro£avin solution (data
not shown).
Perturbation of the pro£avin spectrum occurs upon binding
to the serine proteinases trypsin [8], K-chymotrypsin [9] and K-
thrombin [7,10]. The acridine dye spectrum undergoes a large
increase in absorbance at about 465 nm, which accounts for
the enzyme-pro£avin complex. The spectrum of pro£avin
bound to the thrombin-hirugen complex in the crystal exhibits
a large increase in absorbance at about 465 nm (Fig. 1A),
similar to the value reported for the pro£avin-thrombin com-
plex in saline solution. This suggests that the acridine binding
mode in the crystal is consistent with the binding in solution
and is not signi¢cantly a¡ected by the presence of hirugen at
the exosite of the enzyme nor by the PEG content of the
solution used to stabilise the crystal.
The binding of pro£avin to the thrombin-hirugen crystal is
slow, though clearly speci¢c, as indicated by the high polar-
isation of the absorption bands (Fig. 1A). Incubation with
pro£avin at higher concentrations (Fig. 1B) shows a signi¢-
cant increase in the amount of pro£avin bound compared
with the 0.1 mM incubation. The polarisation ratio is concen-
tration independent, indicating that the binding is still speci¢c
at higher chromophore concentrations (data not shown). In
principle one can estimate the stoichiometry of pro£avin bind-
ing from the relative isotropic absorbance at 280 nm and 465
nm by measuring the components in the three principal opti-
cal directions. In practice it was not possible to make meas-
urements along the z direction in these monoclinic crystals.
The value of the dissociation constant for the binding of pro-
£avin to the crystals (Kd = 0.53 mM) (Fig. 1C) is very much
larger than that reported for the binding of the dye to throm-
bin in aqueous solution at similar pH conditions (KdV10
WM) [7] suggesting that either there is competition between
components of the stabilising solution and pro£avin for the
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Table 1
Crystallographic statistics
Crystallographic statistics
Space group C2
Cell parameters:
a 71.15 Aî
b 72.25 Aî
c 72.67 Aî
L 100.61‡
Resolution range 20.0^2.0 Aî
Measured re£ections 56 491
Unique re£ections 24 042
Rmergea 5.1% (15.8%)b
Completeness 98.1% (94.9%)b
Re¢nement:
Rfactorc 18.9%
Rfreed 21.2%
R.m.s. deviation from ideal bond lengths 0.009 Aî
R.m.s. deviation from ideal bond angles 1.84‡
a Rmerge  100U
P
h
P
j MIhj3IhM=
P
h
P
j Ihj where Ih is the weighted
mean intensity of the symmetry related re£ections Ihj .
bValues for the outermost resolution shell are given in parentheses.
cRfactor  100U
P
MFobs3FcalcM=
P
MFobsM where Fobs and Fcalc are the
observed and calculated structure factors respectively.
dRfree is the Rfactor calculated using a random 5% sample of re£ection
data omitted from re¢nement.
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binding site or the binding is intrinsically weaker in the crys-
talline state. Addition of PPACK to the thrombin-hirugen-
pro£avin crystals results in the progressive disappearance
over 20 h of the 465 nm peak (Fig. 1C), indicating the pres-
ence of overlapping binding sites for pro£avin and PPACK.
3.2. Crystallographic studies
The thrombin-hirugen model of pro£avin complex is essen-
tially identical to the native thrombin-hirugen structure. The
amino terminus (Thr-1H-Glu-1C) and the carboxy terminus
(Ile-14K-Arg-15) of the thrombin A chain are not de¢ned in
the electron density map. There is also no electron density for
the carboxy terminal end (Gly-246-Glu-247) of the thrombin
B chain and the Thr-147-Lys-149E polypeptide segment,
which is part of the 148 insertion loop.
Despite the large heat capacity change reported upon bind-
ing of pro£avin to thrombin [25], the presence of pro£avin
does not result in signi¢cant displacements of the polypeptide
chains with respect to the native structure. Thus the pro£avin
bound and native structures can be superposed with an r.m.s.
deviation of 0.1 Aî . The pro£avin molecule binds in the S1
speci¢city pocket of the protease (Figs. 2 and 3) with one of
the two amino groups of the inhibitor interacting with the
carboxylate of Asp-189 at the bottom of the speci¢city pocket.
In addition, this amino group forms a hydrogen bond to
solvent molecule W2, which bridges to the carbonyl group
of Phe-227. The buried solvent molecule together with W1
(Figs. 2 and 3) are present in other thrombin structures
[5,11,26], as well as in the trypsin pocket [27].
Although the pro£avin amino group interacting with Asp-
189 is located in much the same position as the Arg-3P NH1 in
the PPACK-thrombin structure [1] with the plane of the ac-
ridine ring matching that of the guanidinium moiety, the ori-
entation of the pro£avin molecule is quite di¡erent. The pla-
nar pro£avin interacts with the hydrophobic sides of the S1
pocket, directing one amino group towards Asp-189 and the
other towards the surface of the thrombin molecule rather
than towards the active site Ser-195. This amino group is
not involved in hydrogen bonds and has a larger temperature
factor than the amino group involved in ionic interactions at
the bottom of the pocket. The orientation of the acridine
molecule may be favoured by the hydrogen bond interaction
between the protonated aromatic nitrogen of pro£avin and
the carbonyl group of Gly-219. In the PPACK structure [1],
this carbonyl group forms hydrogen bonds with both the Arg-
3P NH2 and with a water molecule located at the position
occupied by the ring nitrogen of pro£avin. Glu-192 has the
same conformation as in the native model and does not par-
ticipate in the binding of the P1 residue as observed in the
PPACK complex. The active site cleft is occupied by a string
of ordered water molecules that extend from the carbonyl
group of Gly-216.
Pro£avin binding to thrombin is speci¢c and occurs at the
S1 pocket of the enzyme, which physiologically accommo-
dates basic P1 residues with a strong preference for arginine
FEBS 20002 27-3-98
Fig. 1. Spectra of pro£avin bound to crystals of the thrombin-hiru-
gen complex stabilised in a solution containing 25% w/v PEG-4000,
0.2 M NaCl, HEPES 0.1 M pH 7.0. A: Time dependence of the po-
larised absorption spectra of a crystal soaked in 0.1 mM pro£avin.
The spectra were recorded with electric vector of the polarised light
parallel to either the x or y crystal optical directions. B: The e¡ect
on the polarised absorption spectra of varying the pro£avin concen-
tration in the range 0.05 to 0.5 mM. Spectra were recorded with
light polarised along the y direction. C: Spectral changes of the
thrombin-hirugen-pro£avin complex occurring upon PPACK bind-
ing. A crystal was soaked in a solution of pro£avin 0.1 mM and
then transferred to a solution containing both pro£avin 0.1 mM
and PPACK 0.1 mM. Spectra were recorded over 20 h with the
electric vector of polarised light parallel to the y optical axis of the
crystal.
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side chains. Benzamidine is a stronger base (pKa = 11.6) [28]
than pro£avin (pKa = 9.5) [29] but at neutral pH both are
positively charged. In solution, the pro£avin molecule binds
more tightly (KdV10 WM) [7] than benzamidine (Ki = 343
WM) [7] indicating that the presence of a highly basic group
is not an overriding requirement for tight speci¢c binding to
the S1 pocket of thrombin. The pro£avin complex is partly
stabilised by hydrophobic interactions with the upper section
of the speci¢city pocket in a manner similar to that observed
for some peptide boronic acid inhibitors which lack a positive
change at the P1 position [30].
PPACK, which has an extended binding region that in-
cludes the apolar S2 and aryl binding sites as well as the S1
pocket, competes directly with pro£avin as seen in the loss of
the 465 nm absorption peak (Fig. 1C). The crystallographic
results reveal that pro£avin competes with the PPACK Arg-3P
residue for the S1 pocket. It follows that pro£avin displace-
ment can be used to monitor binding of other low molecular
weight inhibitors to the S1 pocket.
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(Generated using the program MOLSCRIPT [32] with modi¢cations by R. Esnouf [33].)
Fig. 3. Schematic representation of the hydrogen bonding between
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ces are given in angstroms.
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